<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Optimer Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/optimer-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Moved Down to Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901</link>
		<comments>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87901</guid>
		<description><![CDATA[We recently downgraded our rating on Optimer Pharmaceuticals Inc. (OPTR) to Neutral from Outperform as we await more visibility on how the commercial launch of its sole marketed antibiotic Dificid (fidaxomicin) takes shape. Optimer launched Dificid in July 2011 in the US for the treatment of clostridium difficile-associated diarrhea (CDAD). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities.  Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid scores better than currently available treatment options on many parameters. Dificid has been shown to be non-inferior to ViroPharma’s (VPHM) Vancocin (the only other FDA approved antibiotic for the treatment of clostridium difficile infection) in late stage studies in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296</link>
		<comments>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296#comments</comments>
		<pubDate>Mon, 15 Aug 2011 13:56:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81296</guid>
		<description><![CDATA[Optimer Pharmaceuticals&#8217; (OPTR) second quarter 2011 loss per share of $0.52 was wider than the year-ago loss, but we are encouraged by the FDA approval and subsequent launch of Dificid, an antibiotic which treats a condition known as CDAD. Dificid scores better than currently available treatment options on many parameters. Particularly, we believe the inclusion of superior recurrence benefits over Vancocin in the product label will provide valuable benefit and help Dificid sales. Further, the deals with Cubist and Astellas are positive for Optimer as it will benefit from their experience in marketing hospital-based antibiotics. Thus, we have an Outperform recommendation on Optimer with a target price of $9.00. Optimer also currently carries a Zacks #1 Rank (Strong Buy). OPTIMER PHARMAC (OPTR): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AIB) Company News for May 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393</link>
		<comments>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393#comments</comments>
		<pubDate>Wed, 18 May 2011 15:20:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Foreign Money Center Banks]]></category>
		<category><![CDATA[AIB]]></category>
		<category><![CDATA[Allied Irish Banks plc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[eLong Inc]]></category>
		<category><![CDATA[Fairpoint Communications Inc.]]></category>
		<category><![CDATA[FRP]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[LINE]]></category>
		<category><![CDATA[Linn Energy Llc]]></category>
		<category><![CDATA[LONG]]></category>
		<category><![CDATA[MAKO]]></category>
		<category><![CDATA[MAKO Surgical Corporation]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[ONCOLYTICS BIOTECH]]></category>
		<category><![CDATA[ONCY]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74393</guid>
		<description><![CDATA[•    Dell Inc. (NASDAQ:DELL) reported Q1 EPS of $0.55, higher than the Zacks Consensus Estimate of $0.43 per share. Revenue for the quarter edged up 1% year-over-year to $15.02 billion, falling short of the Zacks Consensus Estimate of $15.457 billion •    Share prices of US listed Allied Irish Banks, PLC. (NYSE:AIB) rose 13.33% to close at $3.06 after the banking company unveiled a new structure and top management team •    Leerink Swann initiated coverage on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) with an &#8220;Outperform&#8221; rating and a valuation call of $12 to $14 per share •    Share prices of elong, Inc. (NASDAQ:LONG) increased 56.72% on news that China‘s Tencent Holdings has bought a 16% stake in the company for $84.4 million •    Shares of FairPoint Communications, Inc. (NASDAQ:FRP) fell more ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats on One-Time Gain</title>
		<link>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730</link>
		<comments>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730#comments</comments>
		<pubDate>Wed, 11 May 2011 05:28:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73730</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat was due to a huge increase in the top-line in the reported quarter. In the first quarter, revenues were $69.3 million versus $0.30 million in the prior-year quarter. Optimer does not have any marketed products at present. The substantial year-over-year growth was due to the receipt of a one-time $69.2 million upfront payment from Astellas Pharma in exchange for development and commercialization rights for fidaxomicin in certain territories outside US. Fidaxomicin is Optimer’s primary drug candidate which is currently under review both in the US and Europe for the treatment of Clostridium difficile infection (CDI). Fidaxomicin will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:24:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70927</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote its lead pipeline candidate, fidaxomicin, to be sold as Dificid in the US. The collaboration follows on the heels of a US panel backing for Dificid for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD). The FDA decision on Dificid is expected in May 2011. The candidate is also under regulatory review in the EU. Per the terms of the deal, Optimer will book sales on the candidate, if approved. Optimer also retains the new drug application (NDA) for Dificid. It will also be responsible for FDA approval and manufacturing of the candidate. In exchange for its efforts in co-promoting Dificid, Cubist will be entitled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Earns FDA Panel Nod on Dificid Drug</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:10:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70818</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) received a major boost when an advisory panel of the US Food and Drug Administration (FDA) unanimously recommended approval of its lead pipeline candidate, Dificid (fidaxomicin), for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI. CDI is the most common nosocomial or hospital-acquired diarrhea. The Anti-Infective Drugs Advisory Committee (AIDAC) voted 13-0 to recommend approval of the candidate believing that it was safe and efficacious in the treatment of CDI. The positive recommendation was based on combined data from two late-stage studies, which revealed that Dificid was superior to ViroPharma’s (VPHM) Vancocin (the only FDA approved antibiotic for the treatment of CDI) in reducing CDI recurrence by 47%. The data further revealed improved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2010/10/15/optr-optimer-pharmaceuticals-announces-pipeline-progress/55276</link>
		<comments>http://www.stockbloghub.com/2010/10/15/optr-optimer-pharmaceuticals-announces-pipeline-progress/55276#comments</comments>
		<pubDate>Fri, 15 Oct 2010 17:56:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55276</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) announced the submission of the first section of a rolling New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its anti-infective candidate fidaxomicin. Optimer is seeking marketing approval of the candidate for treating patients suffering from clostridium difficile infection (CDI) and for the prevention of the recurrence of the infection. Optimer expects the submission of the rolling NDA to be completed by the year-end. Rolling NDA refers to a process used by the FDA to expedite the review of a drug intended to treat a serious or life-threatening disease. The market for the disease is characterized by a huge unmet need.  Furthermore, the process allows the US regulatory agency to review sections of the NDA as and when they are submitted. Optimer ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/15/optr-optimer-pharmaceuticals-announces-pipeline-progress/55276/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals&#8217; Fidaxomicin Study Report Encourages Company</title>
		<link>http://www.stockbloghub.com/2010/09/17/optr-optimer-pharmaceuticals-fidaxomicin-study-report-encourages-company/52019</link>
		<comments>http://www.stockbloghub.com/2010/09/17/optr-optimer-pharmaceuticals-fidaxomicin-study-report-encourages-company/52019#comments</comments>
		<pubDate>Fri, 17 Sep 2010 15:12:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52019</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals, Inc. (OPTR) received a boost when its candidate fidaxomicin, which is being developed for treating adults suffering from clostridium difficile infection (CDI), fared well in late-stage multi-center, randomized, double-blind studies (n=1,164). Results from the trials, presented at the 50th annual interscience conference on antimicrobial agents and chemotherapy in Boston, revealed that fidaxomicin was superior to vancomycin in treating CDI recurrence and in reducing the probability of another relapse. Vancomycin is the only US Food and Drug Administration (FDA) approved antibiotic for the treatment of CDI. Fidaxomicin scored better than Vancocin in terms of both recurrence and global cure rates. We note that CDI is the most common nosocomial or hospital-acquired diarrhea. CDI is a serious illness caused by infection of the inner lining of the colon by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/17/optr-optimer-pharmaceuticals-fidaxomicin-study-report-encourages-company/52019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Gets Good News</title>
		<link>http://www.stockbloghub.com/2010/08/23/optr-optimer-pharmaceuticals-gets-good-news/49045</link>
		<comments>http://www.stockbloghub.com/2010/08/23/optr-optimer-pharmaceuticals-gets-good-news/49045#comments</comments>
		<pubDate>Mon, 23 Aug 2010 23:37:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49045</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals, Inc. (OPTR) received a boost with the European Medicines Agency accepting the Marketing Authorization Application (MAA) filed by the company for its candidate fidaxomicin. Optimer is seeking marketing approval of the drug for treating patients suffering from clostridium difficile infection (CDI) and for the prevention of the recurrence of the infection in the European Union. The announcement of the submission of the MAA was made by Optimer on August 2, 2010. We note that CDI is the most common nosocomial or hospital-acquired diarrhea. CDI is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria that produces toxins resulting in inflammation, severe diarrhea and sometimes death. CDI accounts for approximately 20% of the antibiotic-associated diarrhea incidences as well as many cases of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/23/optr-optimer-pharmaceuticals-gets-good-news/49045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Signs Manufacturing Deal</title>
		<link>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389</link>
		<comments>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389#comments</comments>
		<pubDate>Tue, 25 May 2010 22:15:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38389</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) entered into a long-term supply agreement with India based Biocon Limited. The agreement is aimed at manufacturing the active pharmaceutical ingredient of fidaxomicin, Optimer’s lead candidate. Fidaxomicin is being developed to treat Clostridium difficile infection (CDI), the most common nosocomial or hospital-acquired, diarrhea. Following positive results from the second phase III trial of the drug in February 2010, Optimer is preparing to submit a new drug application in the second half of 2010. We believe the agreement with Biocon is a step towards the preparatory groundwork. While Optimer currently holds worldwide rights to fidaxomicin, it is on the lookout for a suitable partnership for the commercialization of fidaxomicin outside North America. Optimer also plans to submit a Marketing Authorization Application (MAA) for fidaxomicin with the European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Reports Positive Phase III Data</title>
		<link>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422</link>
		<comments>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422#comments</comments>
		<pubDate>Mon, 12 Apr 2010 17:24:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33422</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) presented positive data from a final stage trial of one of its lead candidates, fidaxomicin. The second phase III study was conducted in patients with Clostridium difficile infection (CDI). The data were presented at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria. The phase III trial, conducted in two phases enrolled over 1,100 patients. The second phase III trial, conducted in about 100 clinical sites in North America and Europe with 535 patients, was aimed at comparing the safety and effectiveness of fidaxomicin with that of Vancocin. It was observed that fidaxomicin met the primary endpoint of non-inferiority compared to Vancocin. Moreover, fidaxomicin scored better than Vancocin on both recurrence rates and global cure rates. We note that these ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals&#8217; Loss Narrows</title>
		<link>http://www.stockbloghub.com/2010/03/12/optr-optimer-pharmaceuticals-loss-narrows/30509</link>
		<comments>http://www.stockbloghub.com/2010/03/12/optr-optimer-pharmaceuticals-loss-narrows/30509#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:48:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30509</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) fourth quarter loss per share came in at 28 cents, narrower than the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 31 cents. For 2009, the company reported a loss per share of $1.30 compared to a loss of $1.24 in 2008. Optimer does not have any marketed products at present. It derives revenues primarily from research grants and collaborative agreements. The company reported revenues of $0.2 million, an increase of 62% compared to the corresponding quarter of 2008. Revenues during 2009 came in at $0.9 million compared to $1.02 million. Current investor focus is more on the development of the company’s portfolio rather than the financials. The company has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Both fidaxomicin and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/optr-optimer-pharmaceuticals-loss-narrows/30509/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/11/optr-optimer-pharma-beats-estimates/20293</link>
		<comments>http://www.stockbloghub.com/2009/11/11/optr-optimer-pharma-beats-estimates/20293#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:40:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20293</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) third quarter loss per share came in at 28 cents, better than the Zacks Consensus Estimate of a loss of 36 cents and loss of 31 cents reported in the year-ago period. The company does not have any marketed products at present; it derives revenues primarily in the form of research grants and from collaborative agreements. The company reported revenues of $0.18 million, a decline of 26.3% compared to the corresponding quarter of last year. We believe current investor focus is more on the development of the company’s portfolio rather than the financials. Operating expenses during the quarter were $9.6 million, marginally down from $9.8 million reported in the year ago period. While R&#38;D and marketing expenses did not change much, general and administrative expenses increased 31% compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/optr-optimer-pharma-beats-estimates/20293/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

